Acute Kidney Injury (AKI) Treatment Market advancements were driven by increasing incidence worldwide of AKI. New diagnostic technologies, including biomarkers and advanced imaging, enabled early detection enabling more effective management. These tools have improved patient outcomes which should spur market expansion over the coming years.
Late 2023 saw several
pharmaceutical companies making significant strides toward clinical trials focused on kidney regeneration and personalized treatments for AKI. Their therapies aim to decrease mortality rates while speeding recovery times for critical care settings; further, innovation presents significant opportunities for market expansion as new treatments emerge on the market.
Acute kidney injury treatment involves addressing the underlying cause, such as dehydration, infection, or medication toxicity. These injuries are sudden loss of kidney function, typically developing over hours to days. Acute kidney injury arises from many conditions, including dehydration, severe infections, toxic effects of drugs, or reduced blood flow to the kidneys due to conditions like heart failure. This could lead to the accumulation of waste products, electrolytes, and fluid imbalances in the body.
Due to an increasing global prevalence of Acute Kidney Injury (AKI), its Treatment Market has experienced tremendous expansion. By 2023, hospitalized patient AKI incidence ranged between 5-7% globally with critical care units reporting higher incidence. Studies indicate AKI accounts for 20%-30% of ICU admissions thus emphasizing its necessity as effective treatments must be found fast.
According to recent data, approximately 2 million cases of AKI are reported annually worldwide, with 40% to 60% of these cases occurring in developed countries. The mortality rate for severe AKI remains high, at around 30% to 50% in ICU patients, underscoring the need for advanced therapies. The growing awareness and investments in kidney care are contributing to increased demand for better diagnostic tools and treatment solutions in the AKI segment.
Pharmaceutical and healthcare provider investments in AKI research are also increasing, with pharmaceutical companies and providers increasingly prioritizing kidney health as an area for investment. Emerging markets, particularly Asia-Pacific and Latin America are seeing rising demand for advanced renal care solutions - thanks to improved healthcare infrastructure these regions will likely experience exponential market expansion that presents ample opportunity for product launch or penetration strategies.
The US Acute Kidney Injury Treatment Market
The US acute kidney injury treatment market is projected to reach USD 582.1 million by the end of 2024 and grow steadily to reach a total value of USD 1,100.0 million by 2033 with an expected CAGR of 7.3%.
The acute kidney injury treatment market is driven by the rising prevalence of chronic diseases like diabetes and hypertension, which increase the risk of acute kidney injury. Aging populations, advancements in diagnostic techniques, and increased awareness of kidney
health in the US also contribute to market growth.
Growing adoption of advanced diagnostic tools and the use of biomarkers for early detection & monitoring of acute kidney injury are some of the key trends in the US. There is a significant focus on developing innovative therapies, including regenerative medicine and stem cell treatments, aimed at restoring kidney function.
Key Takeaways
- Market Growth: The global acute kidney injury treatment market is expected to grow by USD 1,738.8 million, at a CAGR of 7.8 %, during the forecasted period i.e. from 2025 to 2033.
- Market Definition: Acute kidney injury treatment involves managing the underlying cause, restoring kidney function, and preventing complications.
- Injury Analysis: In terms of injury, pre-renal kidney injury is predicted to lead the global market with a high revenue share of 40.9 % in 2024.
- Treatment Type Analysis: Based on the treatment type, dialysis is expected to dominate the global market with a high revenue share in 2024.
- End User Analysis: Hospitals are anticipated to lead the market with the largest revenue share of 47.9 % by the end of 2024.
- Regional Analysis: North America is predicted to dominate the acute kidney injury treatment market with the highest market share of 35.6 % in 2024.
Use Cases
- Early Intervention: Continuous monitoring of kidney function and early intervention can help in identifying and treating acute kidney injury before it progresses to more severe stages.
- Renal Replacement Therapy: RRT like dialysis or hemofiltration is used for patients with severe AKI or those who do not respond to other treatments.
- Pharmacologic Intervention: It involves using medications to address the underlying causes or complications associated with the acute kidney condition.
- Fluid Management: This treatment involves careful fluid management to prevent dehydration or fluid overload as patients with kidney conditions may experience fluid imbalances due to impaired kidney function.
Market Dynamic
Drivers
Rise of Acute Kidney Injury
There are growing conditions of acute kidney injury, primarily due to factors like aging populations, increasing prevalence of chronic diseases like diabetes & hypertension, and an increasing number of surgical procedures, which is a significant driver for the acute kidney injury treatment market.
Role of Artificial Intelligence in Automated Dialysis
Integration of
artificial intelligence and technological advancements in acute kidney injury stage one treatment is driving the acute kidney injury treatment market. Automated dialysis systems can manage all parameters automatically enhancing patient care by minimizing the need for human intervention.
Opportunities
Development of Novel Therapeutics
The adoption of novel therapeutics specifically targeted at treating acute kidney injury is presenting growth opportunities for the market. pharmaceutical companies are focusing on innovative treatment approaches with a deeper understanding of the underlying pathophysiology of acute kidney injury. These novel techniques transform acute kidney injury treatment and improve patient prognosis significantly.
Trends
Increasing Adoption of Biomarkers
The use of biomarkers for the early detection of acute kidney injury is becoming an increasingly popular trend in this market. Biomarkers like neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 are gaining popularity in clinical practice, offering a more precise and timely diagnosis of acute kidney injury, which leads to more targeted & effective treatment strategies.
Restraints
High-cost treatment
Acute kidney injury treatment involves hospitalization, dialysis, and the use of advanced therapeutics which is very costly and poses a restraint on the growth of the market. This high-cost treatment can be challenging for both low- and middle-income countries, where healthcare resources and insurance coverage may be limited, hindering the growth of effective acute kidney injury treatment.
Research Scope and Analysis
By Injury
Pre-renal Kidney Injury is expected to lead the acute kidney injury treatment market with a market
share of 40.9% by 2024 as it represents one of the most frequently occurring forms of acute kidney injury. Dehydration, heart failure, and bleeding from surgery or trauma are often responsible for sudden reductions in the kidney's blood supply, interfering with their ability to filter waste out and balance fluid levels effectively.
Other common factors contributing to kidney injuries may also play a part. These injuries may be reversed with timely, appropriate therapy; restoration of adequate blood flow with effective therapeutic options should restore adequate flow to restore optimal condition, emphasizing their importance as timely treatments may prevent irreparable renal damage from arising.
Otherwise, progressive damage could ensue, including irreversible intrinsic kidney disease if left untreated properly. Due to their prevalence and relatively high success rate in treating prerenal acute kidney injury through rehydration and management of any associated conditions, prerenal acute kidney injury treatments hold a significant market share. Pre-renal kidney injury remains one of the leading global healthcare issues, due to chronic diseases like diabetes & hypertension that increase risk. Furthermore, advances in diagnostic technologies, and healthcare professional awareness of pre-renal kidney injury early detection & management services drive the growth of this market segment.
Postrenal kidney injury occurs due to obstruction of urine flow, leading to increased pressure in the urinary tract and subsequent damage of kidney tissue. BPH (benign prostatic hyperplasia) and cancer among older populations contribute significantly to postrenal kidney injury cases.
By Treatment Type
Dialysis is predicted to dominate the global acute kidney injury treatment market with a revenue share of 55.5% in 2024 as it improves the survival rates of critically ill patients suffering from acute kidney injury. It can rapidly replace critical kidney functions, such as waste filtration, electrolyte balance, and fluid removal, essential in severe acute kidney injury cases. Dialysis has immediate life-saving capability and is crucial in acute settings where kidney function declines rapidly.
Unlike drug therapies that take longer to show effects, they provide quick relief and stabilization. The increasing incidence of kidney injuries requires dialysis as the first line of treatment to prevent complications and support recovery. Strict treatment protocols and extensive clinical evidence support dialysis’s efficacy and safety, reinforcing its dominance in this market.
The global availability of dialysis machines and trained personnel in hospitals and critical care units ensures its immediate use. They are also versatile across a broad range of patient conditions, including severe infections and sepsis, which makes them indispensable.
After Dialysis, Drug therapy is being used for acute kidney injury which includes diuretics, antibiotics, fluid replacement therapy, and other medications. Diuretics help manage fluid overload and reduce swelling, but their effectiveness in improving outcomes is debated, which driving the growth of this segment.
By End User
Hospitals are projected to lead the global acute kidney injury treatment market in terms of
revenue in 2024 with a 47.9% market share due to their access to advanced
medical technology like dialysis machines that enable effective care in severe acute kidney injury cases. Hospitals offer intensive care units and nephrology departments that specialize in acute medical conditions such as kidney stones.
Their team of specialized healthcare providers, such as nephrologists, critical care specialists, nurses, and others offer expert patient care services. Attentive management of acute kidney injury includes both primary kidney issues and complications as well as emergency services that provide quick intervention when necessary for kidney patients whose conditions deteriorate quickly. Supportive treatments, including drug therapies (diuretics, antibiotics, and fluid replacement) complement dialysis for holistic care of renal patients.
Ambulatory surgical centers (ASCs) have become the go-to option in acute kidney injury treatment after hospitals due to their ability to offer high quality, cost-efficient care while offering outpatient solutions for less serious cases, which means less hospital admissions are necessary.
The Global Acute Kidney Injury Treatment Market Report is segmented based on the following:
By Injury
- Pre-renal Kidney Injury
- Post-renal Kidney Injury
- Intrinsic Kidney Injury
By Treatment Type
- Dialysis
- Drug Therapy
- Diuretics
- Antibiotics
- Fluid Replacement therapy
- Others
- Urinary Implants
By End User
- Hospitals
- Ambulatory Surgical Centers
- Others
Regional Analysis
North America is expected to lead the acute kidney injury treatment market with a revenue
share of 35.6% by 2024 due to high prevalence rates for chronic kidney diseases in its region. Its global dominance can also be attributed to an advanced healthcare infrastructure and substantial investments made in research and development. Furthermore, this region boasts some of the world's most cutting-edge medical centers equipped with cutting-edge technologies for kidney patients' treatment and care.
Institutes and companies across this region have made considerable investments in research and development of treatments for kidney injury. This work includes creating novel biomarkers for early detection, improved dialysis techniques, as well as novel drugs designed to manage renal function.
North American's prevalence of diseases like diabetes, hypertension and cardiovascular diseases contribute to higher instances of kidney damage, while their regulatory establishment supports and expedites new therapy development and approval processes quickly ensuring patients access to cutting-edge and most effective therapies to combat kidney diseases.
By Region
North America
Europe
- Germany
- The U.K.
- France
- Italy
- Russia
- Spain
- Benelux
- Nordic
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- ANZ
- ASEAN
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Egypt
- Rest of MEA
Competitive Landscape
The acute kidney injury treatment market is characterized by a high level of consolidation, with a limited number of dominant players holding significant market share. To enhance their revenue and expand their market presence, these companies are pursuing various strategic initiatives. They are forming strategic partnerships, engaging in product line expansions, and executing mergers and acquisitions to broaden their business operations and footprint.
Leading companies in the AKI treatment sector include Angion Biomedica Corp., AM-Pharma, Quark Pharmaceuticals, Inc., and Baxter International. Major key player are leveraging their resources to innovate and offer advanced solutions for managing and treating acute kidney injury.
Some of the prominent players in the Global acute kidney injury treatment market are:
- Angion Biomedica Corp.
- AM-Pharma
- Quark Pharmaceuticals, Inc.
- Baxter International, Inc.
- Fresenius Medical Care AG & Co. KGaA.
- B. Braun Melsungen AG
- Asahi Kasei Medical Co., Ltd.
- LG Chem
- NIKKISO
- NIPRO Medical
- Novartis, Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Others
Recent Development
- In July 2024, CalciMedica Inc. reported that the initial patient was treated in the KOURAGE Phase 2 trial, which is investigating the use of Auxora™ for severe acute kidney injury (AKI) accompanied by acute hypoxemic respiratory failure (AHRF).
- In February 2024, the FDA approved a new device for treating children with AKI caused by sepsis or other septic conditions who need kidney replacement therapy (KRT).
- In December 2023, the Biomarker Laboratory at Cincinnati Children’s introduced the ProNephro AKI test, also known as the neutrophil gelatinase-associated lipocalin (NGAL) test, designed to help clinicians identify patients at risk for moderate to severe AKI within 48-72 hours in intensive care settings.
- In September 2023, the US FDA approved Jardiance® 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression, as announced by Boehringer Ingelheim and Eli Lilly and Company.
Report Details
| Report Characteristics |
| Market Size (2024) |
USD 1,944.4 Mn |
| Forecast Value (2033) |
USD 3,818.9 Mn |
| CAGR (2024-2033) |
7.8% |
| Historical Data |
2018 – 2023 |
| The US Market Size (2024) |
582.1 Mn |
| Forecast Data |
2025 – 2033 |
| Base Year |
2023 |
| Estimate Year |
2024 |
| Report Coverage |
Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors and etc. |
| Segments Covered |
By Injury (Pre-renal Kidney Injury, Post-renal Kidney Injury, and Intrinsic Kidney Injury), By Treatment Type (Dialysis, Drug Therapy, and Urinary Implants), By End User (Hospitals, Ambulatory Surgical Centers, and Others) |
| Regional Coverage |
North America – The US and Canada; Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe; Asia- Pacific– China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, & Rest of MEA
|
| Prominent Players |
Angion Biomedica Corp., AM-Pharma, Quark Pharmaceuticals, Inc., Baxter International, Inc., Fresenius Medical Care AG & Co. KGaA., B. Braun Melsungen AG, Asahi Kasei Medical Co., Ltd., LG Chem, NIPRO Medical, Novartis, Pfizer Inc., and Other Key Players |
| Purchase Options |
HVMN Inc., Thync Global Inc., Apple Inc., Fitbit Inc., TrackmyStack, OsteoStrong, The ODIN, Thriveport LLC, Muse, Moodmetric, and Other Key Players |